122 related articles for article (PubMed ID: 2960008)
1. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
Gonsette RE; Defalque A; Demonty L
Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
[TBL] [Abstract][Full Text] [Related]
2. The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis.
Brinkman CJ; Nillesen WM; Hommes OR
Acta Neurol Scand; 1984 Feb; 69(2):90-6. PubMed ID: 6231801
[TBL] [Abstract][Full Text] [Related]
3. Study of serial lymphocyte subsets in multiple sclerosis: their possible role in the evaluation of disease progression.
Cazzullo CL; Zaffaroni M; Caputo D; Ghezzi A
Riv Neurol; 1987; 57(1):24-6. PubMed ID: 2957783
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
Dawson DM; Carter JL; Hafler DA; Weiner HL
Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood B and T-lymphocyte populations in patients with multiple sclerosis. Relationship with clinical activity of the disease and chronic immunosuppressive treatment.
Chalon MP; Sindic CJ; Boon L; Laterre EC
Acta Neurol Belg; 1987; 87(5):245-60. PubMed ID: 3501665
[TBL] [Abstract][Full Text] [Related]
6. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
7. Correlation of clinical and immunologic states in multiple sclerosis.
Mickey MR; Ellison GW; Fahey JL; Moody DJ; Myers LW
Arch Neurol; 1987 Apr; 44(4):371-5. PubMed ID: 2950845
[TBL] [Abstract][Full Text] [Related]
8. High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Gladstone DE; Golightly MG; Brannagan TH
J Neuroimmunol; 2007 Oct; 190(1-2):121-6. PubMed ID: 17854912
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid and peripheral blood lymphocyte subpopulations in multiple sclerosis. Evaluation by means of monoclonal antibodies (a preliminary note).
Biglino A; Baggio GF; Gioannini P; Mombelli A
Boll Ist Sieroter Milan; 1982; 61(5):432-6. PubMed ID: 6242102
[TBL] [Abstract][Full Text] [Related]
10. A serial study of peripheral blood T lymphocyte subsets in relapsing-remitting multiple sclerosis.
Kastrukoff LF; Paty DW
Ann Neurol; 1984 Mar; 15(3):250-6. PubMed ID: 6232891
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period.
Hauser SL; Reinherz EL; Hoban CJ; Schlossman SF; Weiner HL
Ann Neurol; 1983 Apr; 13(4):418-25. PubMed ID: 6220668
[TBL] [Abstract][Full Text] [Related]
12. Childhood multiple sclerosis: clinical features and demonstration of changes in T cell subsets with disease activity.
Hauser SL; Bresnan MJ; Reinherz EL; Weiner HL
Ann Neurol; 1982 May; 11(5):463-8. PubMed ID: 6213188
[TBL] [Abstract][Full Text] [Related]
13. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
[TBL] [Abstract][Full Text] [Related]
14. T lymphocyte redistribution between peripheral blood and cerebrospinal fluid in active multiple sclerosis.
Biglino A; Baggio GF; Gioannini P
Boll Ist Sieroter Milan; 1984 May; 63(2):150-3. PubMed ID: 6235822
[TBL] [Abstract][Full Text] [Related]
15. New immunosuppressants with potential implication in multiple sclerosis.
Gonsette RE
J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
[TBL] [Abstract][Full Text] [Related]
16. Fluctuations of CD4+ T-cell subsets in remitting-relapsing multiple sclerosis.
Rose LM; Ginsberg AH; Rothstein TL; Ledbetter JA; Clark EA
Ann Neurol; 1988 Aug; 24(2):192-9. PubMed ID: 2972250
[TBL] [Abstract][Full Text] [Related]
17. Suppressor T-lymphocytes in multiple sclerosis: analysis of patients with acute relapsing and chronic progressive disease.
Paty DW; Kastrukoff L; Morgan N; Hiob L
Ann Neurol; 1983 Oct; 14(4):445-9. PubMed ID: 6227277
[TBL] [Abstract][Full Text] [Related]
18. Helper/suppressor ratio in multiple sclerosis.
Thompson AJ; Brazil JK; Whelan CA; Hutchinson M; Feighery C
Ir Med J; 1984 Apr; 77(4):119. PubMed ID: 6234258
[No Abstract] [Full Text] [Related]
19. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
Jeffery DR
J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559
[TBL] [Abstract][Full Text] [Related]
20. [T lymphocyte subsets in alveolar lavage and peripheral blood in sarcoidosis and extrinsic allergic alveolitis].
Desrues B; Delaval P; Genetet N; Kernec J; Pencolé C; Merdrignac G; Cornillet B; Genetet B
Pathol Biol (Paris); 1987 Dec; 35(10):1301-8. PubMed ID: 2963992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
